| Literature DB >> 36078029 |
Hanxiao Zhu1,2, Wei Wang3, Yun Li1,2.
Abstract
Autophagy is an evolutionally conserved degradation mechanism for maintaining cell homeostasis whereby cytoplasmic components are wrapped in autophagosomes and subsequently delivered to lysosomes for degradation. This process requires the concerted actions of multiple autophagy-related proteins and accessory regulators. In neurons, autophagy is dynamically regulated in different compartments including soma, axons, and dendrites. It determines the turnover of selected materials in a spatiotemporal control manner, which facilitates the formation of specialized neuronal functions. It is not surprising, therefore, that dysfunctional autophagy occurs in epilepsy, mainly caused by an imbalance between excitation and inhibition in the brain. In recent years, much attention has been focused on how autophagy may cause the development of epilepsy. In this article, we overview the historical landmarks and distinct types of autophagy, recent progress in the core machinery and regulation of autophagy, and biological roles of autophagy in homeostatic maintenance of neuronal structures and functions, with a particular focus on synaptic plasticity. We also discuss the relevance of autophagy mechanisms to the pathophysiology of epileptogenesis.Entities:
Keywords: autophagosome; autophagy; epilepsy; mTOR; pathological mechanism; synapse
Mesh:
Year: 2022 PMID: 36078029 PMCID: PMC9455075 DOI: 10.3390/cells11172621
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 7.666
Figure 1Timeline of historical events in autophagy. This timeline depicts the key discoveries of autophagy. Unfortunately, it is not possible to include all discoveries due to limited space.
Figure 2Schematic for macroautophagy. Macroautophagy is a multistep process that involves the induction/initiation, nucleation/expansion, maturation, trafficking of autophagosome, formation of autophagolysosome, and release and reuse of degradation products.
Figure 3Overview of upstream signaling pathways that regulate macroautophagy. Autophagy induction is initiated when mTOR signaling is suppressed by a range of stress modalities and an upstream signaling cascade. Abbreviations: PKB, protein kinase B; AMPK, AMP-activated protein kinase; TSC1, tuberous sclerosis complex 2; TSC2, tuberous sclerosis complex 2; mTOR, mammalian target of rapamycin.
Figure 4Schematic diagram of vesicle nucleation in macroautophagy. Vesicle expansion is orchestrated by Atg proteins and complexes, such as the class III PI3K complex. Abbreviations: 3-MA, 3-methyl adenine.
Figure 5Schematic representations of vesicle elongation events. The elongation of the isolation membrane is mainly directed by two ubiquitin-like protein conjugation pathways. Abbreviations: PE, phosphatidylethanolamine.
Figure 6Schematic for the trafficking of autophagosome, formation of autophagolysosome, and release and reuse of degradation products in macroautophagy. Abbreviations: SNAREs, the soluble N-ethylmaleimide sensitive fusion protein attachment protein receptor.
Figure 7Neurons have unique architectures and characteristics.
Figure 8The cross-regulation between neuronal autophagy and synaptic vesicles at the pre-synaptic and post-synaptic terminals. Neuronal activity induces autophagosome formation at the presynaptic terminal by regulating several presynaptically enriched adaptors (such as Synaptojanin1, Endophilin A, and Bassoon) and regulatory proteins (a). At the postsynaptic terminal, neuronal activity also upregulates neuronal autophagy, resulting in endocytic removal of neurotransmitter receptors (such as GABAAR, NMDAR, and AMPAR) from the plasma membrane, presumably by modulating receptor adaptor proteins (b).
The autophagy-related molecular changes in epilepsy animal models and patients.
| Models/Patients | Molecular Changes | Pathological Changes | References |
|---|---|---|---|
| Lafora disease mice | Increased Rab5, p62 protein level, | Generalized stimulus-sensitive tonic-clonic seizures | Puri and Suzuki., 2012 [ |
| Pilocarpine-induced model mice | Increased levels of Beclin 1, ATG5, ATG7 and the ratio of LC3II/I | Epilepsy | Ying et al., 2020 [ |
| N-ethyl-N-nitrosourea (ENU)-induced mice mutants | Cortical atrophy, dysplasia, and epilepsy | Gstrein et al., 2018 [ | |
| TSC1/PTEN KO mice | mTOR hyperactivation, | Epileptogenesis | Yasin et al., 2013 [ |
| Kainic acid treatment mice | Increased LC3-II levels, elevated ratios of phospho-mTOR/mTOR | Repeated seizures | Shacka et al., 2007 [ |
| Atg7 KO mice | p62 accumulation | Spontaneous seizures | McMahon et al., 2012 [ |
| Depdc5 KO mice | Increased mTORC1 signaling | Spontaneous seizures | Yuskaitis et al., 2018 [ |
| PTEN KO mice + mTOR inhibition | Decreased mTOR activity | Decreased the seizure frequency and death rate | Kwon et al., 2003 [ |
| Pilocarpine-induced model rats | Increased LC3-II/LC3-I ratio and beclin1 level | Status epilepticus | Cao et al., 2009 [ |
| Kainic acid treatment rats | mTOR activation | Status epilepticus | Macias et al., 2013 [ |
| Kainic acid treatment rats + rapamycin | Decreased mTOR activity | Reduced epilepsy | Zeng et al., 2009 [ |
| Pilocarpine-induced model rats | mTOR activation | Status epilepticus | Buckmaster et al., 2009 [ |
| Pilocarpine-induced model rats + rapamycin | Decreased mTOR activity | Reduced seizure activity | Huang et al., 2010 [ |
| Infantile spams/West syndrome rats | mTORC1 pathway overactivation | Spasms, epileptic encephalopathies | Raffo et al., 2011 [ |
| p62 accumulation | Cortical atrophy, late-onset epilepsy | Gstrein et al., 2018 [ | |
| Beta-propeller protein-associated neurodegeneration patients | Developmental and epileptic encephalopathies | Carvill et al., 2018 [ | |
| Autosomal dominant lateral temporal epilepsy patients | Epilepsy | Dazzo and Nobile., 2022 [ | |
| Vici syndrome patients | Severe seizure disorder, progressive neurodegeneration | Byrne et al., 2016 [ | |
| Pediatric-onset ataxias patients | Progressive cerebellar neurodegeneration, developmental delay, intellectual disability, and seizures | Akizu et al., 2015 [ | |
| Ohtahara syndrome patients | Intractable seizures and profound developmental disability | Esposito et al., 2019 [ | |
| Children with | Increased LC3-II/LC3-I ratio | Focal and generalized seizures | Ortiz-González et al., 2018 [ |
| Epilepsy patients | Late-onset epilepsy, temporal lobe epilepsy | Zhang et al., 2021 [ | |
| Focal cortical dysplasia in childhood | mTOR activation, p62 accumulation, | Epilepsy | Yasin et al., 2013 [ |
| Human TSC patients | Increased in Ulk1 phosphorylation, p62 accumulation | Cognitive dysfunction, early-onset, intractable epilepsy | McMahon et al., 2012 [ |
| Hippocampal neuronal culture model of acquired epilepsy | Elevated LC3-II/LC3-I ratio | Acquired epilepsy | Xie et al., 2020 [ |